Cinnamon for PCOS

Verdict: Weak, low-quality evidence for PCOS

Cinnamon shows a weak, preliminary signal for improving insulin resistance and menstrual regularity in PCOS, but the trials are small and low quality, no major clinic or PCOS guideline endorses it, and it is not a proven treatment.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade is weak because the human trials in PCOS are few, small, and methodologically limited. A pilot RCT (PMID 24813595, n=45) reported more frequent menstrual cycles on 1.5 g/day cinnamon, but 28 of 45 women dropped out, undermining the result. A better-conducted RCT (PMID 29250843, n=66) found significant drops in fasting insulin and HOMA-IR. Three meta-analyses (PMIDs 32151755, 33111340, 37316893) agree cinnamon modestly lowers HOMA-IR and fasting glucose, yet each pools small heterogeneous studies and is itself rated low quality.

Crucially, every trial measures only surrogate metabolic markers. None tests the outcomes that matter most in PCOS, ovulation, pregnancy, live birth, or hormonal normalization, so a benefit on insulin numbers cannot be assumed to translate into real clinical improvement. The 2023 umbrella analysis (PMID 37316893) also blends type 2 diabetes with PCOS, so the PCOS-specific effect cannot be cleanly isolated.

Authoritative bodies do not back this use. The FDA classifies cinnamon only as a flavoring agent, and the WHO monograph endorses it solely for appetite loss and indigestion, not blood sugar or PCOS. Mayo Clinic, Cleveland Clinic, Harvard Health, and NIH ODS take no position on cinnamon for PCOS, and the international PCOS guideline omits it entirely. Cassia cinnamon also carries a coumarin-related liver-toxicity risk at supplemental doses and may interact with glucose-lowering drugs, so it should not replace standard care.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.61
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
71%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L11 AI re-checkIndependent read
0.50
L3 MechanismPlausibility
0.65
L2 PubMedPrimary literature
0.75
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.613
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 1 negative)
  4. tier_strict_requirement_check — | B→C 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Preliminary evidence that cinnamon improves menstrual cyclicity in women with polycystic ovary syndrome
PMID: 24813595 2014 RCT (double-blind) n = 45
Finding: Cinnamon group had more frequent menstrual cycles vs placebo (median 0.75 vs 0.25 cycles/month; p=0.0085); high dropout (28/45 completed).
🟠 Limited quality Academic Effect size: MD +0.50 cycles/month
View on PubMed
Insulin resistance improvement by cinnamon powder in polycystic ovary syndrome: A randomized double-blind placebo controlled clinical trial
PMID: 29250843 2018 RCT (double-blind) n = 66
Finding: Fasting insulin (p=0.024) and HOMA-IR (p=0.014) significantly reduced vs placebo; LDL also reduced (p=0.049 vs placebo); other outcomes non-significant.
View on PubMed
Effects of cinnamon on controlling metabolic parameters of polycystic ovary syndrome: A systematic review and meta-analysis
PMID: 32151755 2020 統合分析
Finding: Significant reductions in fasting blood sugar (WMD -5.32 mg/dL), fasting insulin (WMD -4.10 μIU/dL), and HOMA-IR (WMD -0.69); no significant effect on body weight or BMI.
🟠 Limited quality Effect size: WMD HOMA-IR -0.69 (95% CI: -1.37 to -0.004)
View on PubMed
The effect of cinnamon supplementation on glycemic control in women with polycystic ovary syndrome: A systematic review and meta-analysis
PMID: 33111340 2021 統合分析
Finding: Cinnamon significantly reduced HOMA-IR in PCOS women (SMD -0.84; 95% CI: -1.52 to -0.16; p=0.010); based on 5 small RCTs.
🟠 Limited quality Effect size: SMD -0.84 (95% CI: -1.52, -0.16)
View on PubMed
The effect of cinnamon supplementation on glycemic control in patients with type 2 diabetes or with polycystic ovary syndrome: an umbrella meta-analysis on interventional meta-analyses
PMID: 37316893 2023 統合分析
Finding: Cinnamon reduced FPG (WMD -10.93 mg/dL), insulin (WMD -2.01 IU/mL), HOMA-IR (WMD -0.61), and HbA1c (WMD -0.10%) across T2D and PCOS populations combined.
🟠 Limited quality Effect size: WMD HOMA-IR -0.61 (95% CI: -0.91, -0.31)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
FLAVORING AGENT OR ADJUVANT source↗
L4b EU EFSA
Cautious
L4d TW TFDA / 衛福部
Cautious
目前並沒有足夠的實證顯示吃肉桂可以達到降血糖的功效,肉桂不能取代任何降血糖藥物。 source↗
L4e WHO
Supportive
WHO Monographs on Selected Medicinal Plants, Volume 1 (Geneva: WHO, 1999), Cortex Cinnamomi (p. 95): Indications — loss of appetite and dyspeptic complaints. Daily dose: 2.0–4.0 g of the drug, or 0.05–0.2 g essential oil in appropriate preparations. source↗
L5a NIH Office of Dietary Supplements
Cautious
L5e Specialty Society (condition-mapped)
Not addressed
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-pcos-INT-cinnamon-001 繁體中文版 →